{"id":576,"date":"2026-08-11T19:56:39","date_gmt":"2026-08-11T19:56:39","guid":{"rendered":"https:\/\/syrian-biomedica.com\/wissam-dahi\/"},"modified":"2026-08-15T09:11:26","modified_gmt":"2026-08-15T09:11:26","slug":"wissam-dahi","status":"publish","type":"page","link":"https:\/\/syrian-biomedica.com\/ar\/wissam-dahi\/","title":{"rendered":"Wissam Dahi"},"content":{"rendered":"<h1><strong>Wissam Dahi<\/strong><\/h1>\n<h1>Wissam Dahi *<br \/>Prof. Majd Mhd Nassouh Aljamaly **<br \/>Prof. Shaza Anwar Al Laham ***<\/p>\n<p>* Master&#8217;s degree &#8211; Pharmacology &amp; Toxicology Department &#8211; Faculty of Pharmacy &#8211; Damascus University<br \/>** Professor &#8211; Biochemistry and Microbiology Department &#8211; Faculty of Pharmacy \u2013 Damascus \u2013 Syria<br \/>*** Professor \u2013Pharmacology &amp; Toxicology Department &#8211; Faculty of Pharmacy \u2013 Damascus \u2013 Syria<\/h1>\n<div>\n<p><strong>Teriflunomide Exhibits Additive Anti-Cancer Activity with Tamoxifen and Attenuates Its Antagonism with Vitamin D3 in MCF-7 Breast Cancer Cells<\/strong><\/p>\n<\/div>\n<div>\n<p>Combining repurposed drugs with tamoxifen (Tam) provides a powerful targeted strategy to mitigate chemotherapy-induced toxicities in breast cancer. This investigation aimed to evaluate the combinatorial effects of Tam, teriflunomide (Ter), a repurposed immunomodulatory drug, and Vitamin D3 (Vit. D3) in both dual and triple regimens against MCF-7 cells. Utilizing the MTT assay, flow cytometry, and Annexin V\/PI staining, we assessed cytotoxicity, cell cycle progression, and apoptotic activity, respectively, with synergy quantified via the Chou-Talalay method. Our results revealed that IC\u2085\u2080 value for Tam+ Ter combination was 12.999\u00b1 0.071 \u03bcM, with combination index CI= 1.093, indicating an additive pharmacological activity, accompanied by an increased total apoptotic ratio (48.39%) compared to Tam monotherapy (38.44%), and a strong S-phase accumulation. Conversely, the Tam+ Vit. D3 regimen yielded an IC50= 171.816\u00b1 11.937 \u03bcM, with CI= 11.72, demonstrating a very strong antagonistic relationship, with a total apoptotic ratio of 41%, accumulating the majority of cells in the G1 phase. Notably, the triple combination Tam+ Ter+ Vit. D3 resulted in IC50= 24.044\u00b1 1.453 \u03bcM and a CI= 1.35, showing a moderate antagonistic effect, alongside a massive S-phase arrest and near-elimination of the G2 phase. In summary, our findings reveal that while teriflunomide significantly potentiates the anti-cancer activity of tamoxifen through enhanced apoptosis, inhibition of proliferation, and cell cycle arrest, the dual Tam+ Vit. D3 regimen paradoxically yielded antagonistic efficacy. Most importantly, adding teriflunomide to the Tam+ Vit. D3 combination mitigates this negative interaction, shifting it from strong to slight antagonism.<\/p>\n<\/p>\n<p><strong><u>Keywords<\/u>:<\/strong><\/p>\n<p>Tamoxifen; Teriflunomide; Vitamin D3; Combination therapy; Breast cancer<\/p>\n<\/div>\n<p><!--more--><br \/>\n<!-- {\"type\":\"layout\",\"children\":[{\"name\":\"Terms\",\"type\":\"section\",\"props\":{\"image_position\":\"center-center\",\"style\":\"default\",\"title_breakpoint\":\"xl\",\"title_position\":\"top-left\",\"title_rotation\":\"left\",\"vertical_align\":\"\",\"width\":\"small\"},\"children\":[{\"type\":\"row\",\"children\":[{\"type\":\"column\",\"props\":{\"image_position\":\"center-center\",\"position_sticky_breakpoint\":\"m\",\"width_medium\":\"1-1\"},\"children\":[{\"type\":\"headline\",\"props\":{\"content\":\"<strong>Wissam Dahi<\\\/strong>\",\"image_align\":\"left\",\"image_margin\":\"xsmall\",\"margin_top\":\"remove\",\"title_element\":\"h1\",\"title_style\":\"heading-medium\"}},{\"type\":\"headline\",\"props\":{\"content\":\"Wissam Dahi *<br \\\/>Prof. Majd Mhd Nassouh Aljamaly **<br \\\/>Prof. Shaza Anwar Al Laham ***<br \\\/><br \\\/>* Master's degree - Pharmacology &amp; Toxicology Department - Faculty of Pharmacy - Damascus University<br \\\/>** Professor - Biochemistry and Microbiology Department - Faculty of Pharmacy \\u2013 Damascus \\u2013 Syria<br \\\/>*** Professor \\u2013Pharmacology &amp; Toxicology Department - Faculty of Pharmacy \\u2013 Damascus \\u2013 Syria\",\"title_element\":\"h1\",\"title_style\":\"text-small\"}},{\"type\":\"headline\",\"props\":{\"content\":\"\n\n<p><strong>Teriflunomide Exhibits Additive Anti-Cancer Activity with Tamoxifen and Attenuates Its Antagonism with Vitamin D3 in MCF-7 Breast Cancer Cells<\\\/strong><\\\/p>\",\"image_align\":\"left\",\"image_margin\":\"xsmall\",\"margin_bottom\":\"remove\",\"title_color\":\"muted\",\"title_element\":\"div\",\"title_style\":\"h4\"}},{\"type\":\"text\",\"props\":{\"column_breakpoint\":\"m\",\"content\":\"\n\n<p>Combining repurposed drugs with tamoxifen (Tam) provides a powerful targeted strategy to mitigate chemotherapy-induced toxicities in breast cancer. This investigation aimed to evaluate the combinatorial effects of Tam, teriflunomide (Ter), a repurposed immunomodulatory drug, and Vitamin D3 (Vit. D3) in both dual and triple regimens against MCF-7 cells. Utilizing the MTT assay, flow cytometry, and Annexin V\\\/PI staining, we assessed cytotoxicity, cell cycle progression, and apoptotic activity, respectively, with synergy quantified via the Chou-Talalay method. Our results revealed that IC\\u2085\\u2080 value for Tam+ Ter combination was 12.999\\u00b1 0.071 \\u03bcM, with combination index CI= 1.093, indicating an additive pharmacological activity, accompanied by an increased total apoptotic ratio (48.39%) compared to Tam monotherapy (38.44%), and a strong S-phase accumulation. Conversely, the Tam+ Vit. D3 regimen yielded an IC50= 171.816\\u00b1 11.937 \\u03bcM, with CI= 11.72, demonstrating a very strong antagonistic relationship, with a total apoptotic ratio of 41%, accumulating the majority of cells in the G1 phase. Notably, the triple combination Tam+ Ter+ Vit. D3 resulted in IC50= 24.044\\u00b1 1.453 \\u03bcM and a CI= 1.35, showing a moderate antagonistic effect, alongside a massive S-phase arrest and near-elimination of the G2 phase. In summary, our findings reveal that while teriflunomide significantly potentiates the anti-cancer activity of tamoxifen through enhanced apoptosis, inhibition of proliferation, and cell cycle arrest, the dual Tam+ Vit. D3 regimen paradoxically yielded antagonistic efficacy. Most importantly, adding teriflunomide to the Tam+ Vit. D3 combination mitigates this negative interaction, shifting it from strong to slight antagonism.<\\\/p>\\n\n\n<p><\\\/p>\\n\n\n<p><strong><u>Keywords<\\\/u>:<\\\/strong><\\\/p>\\n\n\n<p>Tamoxifen; Teriflunomide; Vitamin D3; Combination therapy; Breast cancer<\\\/p>\",\"margin\":\"default\"}}]}]}]}],\"version\":\"4.5.32\"} --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Wissam Dahi Wissam Dahi *Prof. Majd Mhd Nassouh Aljamaly **Prof. Shaza Anwar Al Laham *** * Master&#8217;s degree &#8211; Pharmacology &amp; Toxicology Department &#8211; Faculty of Pharmacy &#8211; Damascus University** Professor &#8211; Biochemistry and Microbiology Department &#8211; Faculty of Pharmacy \u2013 Damascus \u2013 Syria*** Professor \u2013Pharmacology &amp; Toxicology Department &#8211; Faculty of Pharmacy \u2013 Damascus [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":"","_et_pb_custom_css":""},"class_list":["post-576","page","type-page","status-publish","hentry"],"_et_pb_custom_css":"","_links":{"self":[{"href":"https:\/\/syrian-biomedica.com\/ar\/wp-json\/wp\/v2\/pages\/576","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/syrian-biomedica.com\/ar\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/syrian-biomedica.com\/ar\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/syrian-biomedica.com\/ar\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/syrian-biomedica.com\/ar\/wp-json\/wp\/v2\/comments?post=576"}],"version-history":[{"count":3,"href":"https:\/\/syrian-biomedica.com\/ar\/wp-json\/wp\/v2\/pages\/576\/revisions"}],"predecessor-version":[{"id":615,"href":"https:\/\/syrian-biomedica.com\/ar\/wp-json\/wp\/v2\/pages\/576\/revisions\/615"}],"wp:attachment":[{"href":"https:\/\/syrian-biomedica.com\/ar\/wp-json\/wp\/v2\/media?parent=576"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}